WEST

Generate Collection

Print

Search Results - Record(s) 1 through 16 of 16 returned.

☐ 1. Document ID: US 20030119064 A1

L4: Entry 1 of 16

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119064

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119064 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffrey R.	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw, De	eso In	nage									

☐ 2. Document ID: US 20030109420 A1

L4: Entry 2 of 16

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109420

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030109420 A1

TITLE: Diagnostic markers of acute coronary syndrome and methods of use thereof

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 Escondido CA US Valkirs, Gunars Dahlen, Jeffrey US San Diego CA US Buechler, Kenneth F. Rancho Santa Fe Kirchick, Howard J. San Diego CA US

US-CL-CURRENT: 514/2; 435/7.1

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Full Tit	le Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Drawi Desc	Image									

☐ 3. Document ID: US 20030100033 A1

L4: Entry 3 of 16

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100033

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030100033 A1

TITLE: Prostate cancer-related compositions, methods, and kits based on DNA

macroarray proteomics platforms

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

RULE-47 NAME CITY STATE COUNTRY Stearns, Mark Villanova PΑ US Hu, Youji Gulph Mills PA US Gulph Mills PΑ US Wang, Min

US-CL-CURRENT: 435/7.23; 435/183, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.2

ABSTRACT:

The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer,

comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

4. Document ID: US 20030082782 A1

L4: Entry 4 of 16

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082782

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082782 A1

TITLE: Polynucleotides encoding a novel metalloprotease, MP-1

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chen, Jian	Princeton	NJ	US	
Feder, John N.	Belle Mead	NJ	US	
Nelson, Thomas C.	Lawrenceville	NJ	US	
Krystek, Stanley R.	Ringoes	NJ	US	
Duclos, Franck	Washington Crossing	PA	US	

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Full Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	
Draww Desc	Image									
							W	W		
-		4 IID. 1	T TC 200	20072010	A 1					
<u>↓</u> 3. 1	Jocumen	t ID:	05 200	30072810 A	A.1					
L4: Entry	5 of 16				F:	ile: PGF	PB		Apr 17,	2003

PGPUB-DOCUMENT-NUMBER: 20030072810

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030072810 A1

TITLE: Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals

PUBLICATION-DATE: April 17, 2003

INVENTOR - INFORMATION:

NAME CTTY STATE COUNTRY RULE-47 Burrell, Robert Edward Sherwood Park TX CA San Antonio Wright, John Barrymore ΤХ US Lam, Kan San Antonio US

US-CL-CURRENT: 424/618; 424/649

ABSTRACT:

The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. In another aspect of the invention, there is provided a method of preventing excessive release of matrix metalloproteinases from an inflammatory cell in a disease condition in a human or an animal by contacting the cell with a therapeutically effective amount of a noble metal in a crystalline form characterized by atomic disorder, or with a solution derived therefrom to provide a modulatory effect on one or more matrix metalloproteinases, wherein the one or more noble metals is formed with atomic disorder, and preferably in a nanocrystalline form. The nanocrystalline antimicrobial or noble metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWC
Draw, D	eso Ir	nage						,		

☐ 6. Document ID: US 20030021854 A1

L4: Entry 6 of 16

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030021854

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030021854 A1

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47
Burrell, Robert Edward Sherwood Park TX CA
Wright, John Barrymore San Antonio TX US
Lam, Kan San Antonio US

US-CL-CURRENT: 424/618; 424/649

ABSTRACT:

The invention relates to a method to induce apoptosis and to inhibit matrix
metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.

Full Title Citation	Front Review Classification	Date Reference	Sequences Atta	achments	KWC
Draw, Desc Image					
7. Documen	nt ID: US 20020172987	A1			

L4: Entry 7 of 16

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020172987

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020172987 A1

TITLE: Methods and reagents for the rapid and efficient isolation of circulating

cancer cells

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Terstappen, Leon W.M.M.	Huntingdon Valley	PA	US	
Rao, Galla Chandra	Princeton	ŊĴ	US	
O'Hara, Shawn Mark	Ambler	PA	US	
Liberti, Paul A.	Haverford	PA	US	
Gross, Steven	Ambler	PA	US	
Doyle, Gerald	Radnor	PA	US	

US-CL-CURRENT: 435/7.23

ABSTRACT:

Methods and compositions are provided for detecting circulating $\underline{\mathsf{tumor}}$ cells and assessing said cells for alterations in $\underline{\mathsf{tumor}}$ -diathesis associated molecules.

Full Title	e Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KUMO	
Drawi Desc	Image									
П 8.	Document	t ID·	US 200	20155440	4 1					
<u> </u>	Documen		05 200	20100	••					
L4: Entry	0 of 16				TO 4	ile: PGP	TD.		Oct 24,	2002

PGPUB-DOCUMENT-NUMBER: 20020155440

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155440 A1

http://westbrs:8002/bin/gate.exe?f=TOC&s...e=USPT,PGPB,JPAB,EPAB,DWPI,TDBD&ESNAME=-

Record List Display

TITLE: Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 Ljubimova, Julia Y. Studio City CA US Ljubimov, Alexander V. Studio City CA US Black, Keith L. Los Angeles US

US-CL-CURRENT: 435/6; 435/7.23

ABSTRACT:

Disclosed is a method of diagnosing the presence of a <u>malignant tumor</u>, including a glioma, in a human subject, which involves detecting overexpression of laminin .alpha.4 subunit protein or laminin .alpha.4-specific MRNA, compared to the expression level in a normal tissue control. Also disclosed are a method of predicting the recurrence of a <u>malignant tumor</u> in a human subject from whom a <u>malignant tumor</u> has been resected and a method of classifying the grade of a <u>malignant tumor</u>, such as a glial tumor, based on a molecular classification.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawe D	esc Ir	nage							

KWIC

9. Document ID: US 20020114848 A1

L4: Entry 9 of 16

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020114848

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020114848 A1

TITLE: Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Woods, Gordon L. Moscow ID US

US-CL-CURRENT: 424/654; 514/171, 514/43

ABSTRACT:

Methods and compositions are provided for decreasing PGE2:PGF2.alpha., regulating ratios of zinc:cadmium and regulating the concentration of zinc, calcium and zinc-containing and PGE2-dependent matrix metalloproteinases in body fluids and tissues of a human. Elevated or otherwise unregulated levels of PGE2, zinc and calcium and elevated concentrations of zinc-containing and PGE2-dependent matrix metalloproteinases have been found to be associated with the development of certain diseases.

Full Title Citation Front Review Classification Date Reference Sequences Attachments

KOMO

☐ 10. Document ID: US 20020081641 A1

L4: Entry 10 of 16

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081641

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020081641 A1

TITLE: Non-invasive enzyme screen for tissue remodelling-associated conditions

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Moses, Marsha A. Brookline MA US Yan, Li Wellesley MA US

US-CL-CURRENT: 435/7.23; 435/23

ABSTRACT:

Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic <u>cancer</u> by the identification of high molecular weight enzyme complexes comprising <u>MMPs</u>.

I	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	
Ī	Draw. D	eso Ir	nage								

KOMO

☐ 11. Document ID: US 20020055158 A1

L4: Entry 11 of 16

File: PGPB

May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055158

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020055158 A1

TITLE: Human tissue inhibitor of metalloproteinase-4

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47

Greene, John M. Gaithersburg MD US Rosen, Craig A. Laytonsville MD US

US-CL-CURRENT: $\frac{435}{184}$; $\frac{435}{320.1}$, $\frac{435}{325}$, $\frac{435}{69.2}$, $\frac{536}{23.2}$

ABSTRACT:

A human tissue inhibitor of metalloproteinases-4 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for the treatment of diseases, including arthritis and <u>cancer</u>. Antagonists against such polypeptides and their use as a therapeutic to resorb scar tissue are also disclosed. Diagnostic assays for detecting levels of human TIMP-4 protein and mutations in human TMP-4 nucleic acid sequence are also disclosed.

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

KWIC

☑ 12. Document ID: US 20020042062 A1

L4: Entry 12 of 16

File: PGPB

Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020042062

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020042062 A1

TITLE: Prostate cancer-related compositions, methods, and kits based on DNA

macroarray proteomics platforms

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY RULE-47 IIS Stearns, Mark Villanova PΑ Hu, Youji Gulph Mills PA US Wang, Min Gulph Mills PA US

US-CL-CURRENT: 435/6; 435/183, 435/325, 435/69.3, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The invention relates to novel nucleic acids encoding a mammalian PCAM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, <u>prostate cancer</u>. The invention further relates to methods of detecting and treating <u>prostate cancer</u>, comprising modulating or detecting PCAM-1 expression and/or production and activity of PCAM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Praw Desc | Image |

KWIC

☐ 13. Document ID: US 6544761 B2

L4: Entry 13 of 16

File: USPT

Apr 8, 2003

US-PAT-NO: 6544761

DOCUMENT-IDENTIFIER: US 6544761 B2

TITLE: Human tissue inhibitor of metalloproteinase-4

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Greene; John M. Gaithersburg MD Rosen; Craig A. Laytonsville MD

US-CL-CURRENT: 435/69.2; 514/12, 530/350, 536/23.5

ABSTRACT:

A human tissue inhibitor of metalloproteinases-4 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for the treatment of diseases, including arthritis and cancer. Antagonists against such polypeptides and their use as a therapeutic to resorb scar tissue are also disclosed. Diagnostic assays for detecting levels of human TIMP-4 protein and mutations in human TIMP-4 nucleic acid sequence are also disclosed.

30 Claims, 10 Drawing figures Exemplary Claim Number: 13 Number of Drawing Sheets: 10

	· ·					
Full Title Citation	Front Review	Classification	Diate	Reference	Sequences	Attachments
Tull Title Citation	FIGUR Medicad	Classification	Vale	Incretelle	ecquences	Attachinents
Drawi Desc Image						

KAOAC

☐ 14. Document ID: US 6214542 B1

L4: Entry 14 of 16 File: USPT Apr 10, 2001

US-PAT-NO: 6214542

DOCUMENT-IDENTIFIER: US 6214542 B1

TITLE: Quantification of indicators of fibrosis

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Striker; Gary E. Bethesda MD
Striker; Liliane J. Bethesda MD
Peten; Emmanuel Bethesda MD

US-CL-CURRENT: 435/6; 435/91.2

ABSTRACT:

The state of the extracellular matrix of discrete tissue subsegments can be determined via an approach that combines microdissection, reverse transcription and polymerase chain reaction. Using this approach, a positive correlation between a fibrotic condition and alterations in messenger RNA levels of matrix components provides the basis for (i) the diagnosis of a fibrotic disease and (ii) the monitoring of the efficacy of a therapeutic regimen.

16 Claims, 1 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 1

Full Title Citation Front Review Classification Date Reference Sequences Attachments

Draw Desc Image

KOMC

☐ 15. Document ID: US 6114316 A

L4: Entry 15 of 16

File: USPT

Sep 5, 2000

US-PAT-NO: 6114316

DOCUMENT-IDENTIFIER: US 6114316 A

TITLE: Combination of bisphosphonate and tetracycline

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

COUNTRY CITY STATE ZIP CODE Ramamurthy; Nungavarm S. Smithtown NY Golub; Lorne M. Smithtown NY Sorsa; Timo A. Helsinski FΙ FΙ Teronen; Olli P. Helsinski Salo; Tuula A. Oulu

US-CL-CURRENT: 514/108; 514/102, 514/103, 514/104, 514/107, 514/152, 514/154

ABSTRACT:

Tissue-destructive conditions related to excess protemase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.

8 Claims, 8 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw, D	eso Ir	nage				-			

KOMC

☐ 16. Document ID: US 5998390 A

L4: Entry 16 of 16

File: USPT

Dec 7, 1999

US-PAT-NO: 5998390

DOCUMENT-IDENTIFIER: US 5998390 A

** See image for Certificate of Correction **

TITLE: Combination of bisphosphonate and tetracycline

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

http://westbrs:8002/bin/gate.exe?f=TOC&s...e=USPT,PGPB,JPAB,EPAB,DWPI,TDBD&ESNAME=-

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ramamurthy; Nungavarm S.	Smithtown	NY		
Golub; Lorne M.	Smithtown	NY		
Sorsa; Timo A.	Helsinki			FI
Teronen; Olli P.	Helsinki			FI
Salo; Tuula A.	Oulu			FI

US-CL-CURRENT: $\underline{514}/\underline{94}$; $\underline{424}/\underline{54}$, $\underline{424}/\underline{57}$, $\underline{514}/\underline{102}$, $\underline{514}/\underline{107}$, $\underline{514}/\underline{108}$, $\underline{514}/\underline{152}$, $\underline{514}/\underline{153}$, $\underline{514}/\underline{154}$, $\underline{514}/\underline{825}$, $\underline{514}/\underline{826}$, $\underline{514}/\underline{866}$, $\underline{514}/\underline{900}$, $\underline{514}/\underline{902}$, $\underline{514}/\underline{903}$, $\underline{514}/\underline{912}$, $\underline{514}/\underline{914}$, $\underline{514}/\underline{925}$

ABSTRACT:

Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.

8 Claims, 8 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw, De	esc li	mage					•			

Generate Collection Print

· Term	Documents
METALLOPROTEINASE	2505
METALLOPROTEINASES	2043
((METALLOPROTEINASE.CLM.) AND 3).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	16
(L3 AND	16

Display Format: - Change Format

METALLOPROTEINASE.CLM.).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.|

Previous Page Next Page

11 of 11

Page 1 of 2

Ralph Gitomer

1/34/1 (Item 1 from file: 347)

03745560 REAGENT FOR LIVER DISEASE DIAGNOSIS

Pub. No.: 04-110660 [JP 4110660 A] **Published:** April 13, 1992 (19920413)

Inventor: OKUBO IWAO SASAKI MINORU

Applicant: GREEN CROSS CORP THE [358747] (A Japanese Company or Corporation), JP (Japan)

Application No.: 02-230169 [JP 90230169]

Filed: August 30, 1990 (19900830)

International Class: [5] G01N-033/53; G01N-033/573

JAPIO Class: 46.2 (INSTRUMENTATION -- Testing); 14.4 (ORGANIC CHEMISTRY -- Medicine);

28.2 (SANITATION -- Medical)

Journal: Section: P, Section No. 1395, Vol. 16, No. 357, Pg. 119, July 31, 1992 (19920731)

ABSTRACT

PURPOSE: To obtain reagent which is useful in the diagnosis of liver disease and has a clinical meaning by preparing the regent using an antibody for the complex of kininogen and calpain.

CONSTITUTION: Macromolecular kininogen is refined by a column chromatography using DEAE-Sephadex and zinc chelate-Sepharose from fresh human plasma. Then, calpain I is refined by a column chromatography using DEAE-cellulose, ultra-gel AcA34, blue Sepharole and DEAE biogel A from human erythrocyte. In order to form a complex, the specified incubation of the mixture of kininogen and calpain in the buffer solution of 5-mM calcium chloride and 20-nM boric acid is performed at the mol ratio of 1:1. Disuccinymicelles pellet of 1mM is further added, and incubation is performed at room temperature. Thus a bridged complex is obtained. As the calpain for preparing the antibody for the complex of kininogen and calpain, calpain I and calpain II especially obtained through a human body, above all through the human erythrocyte, are used, and the antibody is prepared.

JAPIO (Dialog® File 347): (c) 2003 JPO & JAPIO. All rights reserved.

1/34/2 (Item 1 from file: 351)

009045292

WPI Acc No: 1992-172663/199221

Reagent for diagnosis of hepatic disease - comprises antibody prepd. from kiningen which binds to kiningen-calpain complex

A reagent for the diagnosis of hepatic disease which consists of

Patent Assignee: GREEN CROSS CORP (GREC) Number of Countries: 001 Number of Patents: 001 Patent Family: Patent No Kind Date Applicat No Kind Date Week 19920413 JP 90230169 Α 19900830 199221 B Priority Applications (No Type Date): JP 90230169 A 19900830 Patent Details: Patent No Kind Lan Pg Main IPC Filing Notes JP 4110660 Ά 6 Abstract (Basic): JP 4110660 A

antibody to kininogen-calpain complex.

Kininogen used for preparing antibody to kininogen-calpain complex is high molecular kininogen, low molecular kininogen or the H-chain matter, pref. those from human being, esp. human blood plasma. Calpain, Ca-depending protease, used is e.g. calpain I, calpain II, etc., pref. those from human being, esp. human erythrocyte. The kininogen-calpain complex used is a complex which is bound in the presence of bivalent cation such as Ca ion. The molar ratio of kininogen to calpain in the complex is usually 2:1-1:2 (1:1).

The diagnosis of hepatic disease using the reagent is carried out by common immunoassays such as radioimmunoassay, enzyme immunoassay, reversed passive haemagglutination method, etc.. Sample for the diagnosis is e.g. urine, blood, blood plasma or blood serum. The antibody is kininogen-calpain complex is monoclonal antibody or polyclonal antibody prepd. by using the complex as antigen. The monoclonal antibody is obtd. by common cell fusion method. The polyclonal antibody is obtd. from the blood serum of an animal immunised with the complex as antigen. Animal used for the immunisation is e.g. rat, mouse, rabbit, goat or horse.

USE/ADVANTAGE - The invention relates to a reagent for the diagnosis of hepatic disease. The reagent is useful for the diagnosis of hepatic disease such as chronic hepatitis, liver cirrhosis, hepatic carcinoma, A type hepatitis or aggressive hepatitis

Dwg.0/0

Derwent Class: B04; D16; S03

International Patent Class (Additional): G01N-033/53

. Derwent WPI (Dialog® File 351): (c) 2003 Thomson Derwent. All rights reserved.

© 2003 The Dialog Corporation